Relmada Lawsuit against Laidlaw & Company

Relmada is a company that concentrates on the manufacturing of medicines for chronic pain. Recently, the company stated that is planning to make an amendment on a lawsuit they filed made against Laidlaw and Company Ltd. The amendment was to add to some charges filed before in the in the U.S. District Court for the District of Nevada. Relmada claims that Laidlaw disclosed the company’s confidential information, which can negatively impact the company reputation to the investors. Another issue is Relmada is suing for damages caused by the company by Laidlaw by the fees and the costs the company incurred after the company misled them.

Remalda board of directors sat and decided that Laidlaw should compensate for the damages they have caused to the company as a form of punishment to ensure that Laidlaw doesn’t do the same thing to another company in the future. Remalda board of directors claims that they have taken action because they are trying to keep protecting the company and the interest of stakeholders as much as possible.
In December 2015, a temporary restraining order was issued against Laidlaw principles, Matthew Eitner and James Ahern following their misleading proxy materials. The case was then amended on January 2016.

Laidlaw is a 170-year-old company that has been concentrating on the independent and investment banking needs for both domestic and international companies, corporations, private investors, and institutions. The company’s goal is to provide exclusive services to both emerging and existing companies. The company is headed by Matthew D. Eitner who serves as the Chief Executive Officer and James P. Ahern who is the Managing partner and the head of Capital Markets. Both of the parties were involved in the lawsuit filed by Relmada. Although the company has been facing the charges, it has built an excellent reputation for the 170 years it has been in operation.

Laidlaw & Company Suit Gets a Restraining Order over Dissemination of Misleading Information

Dan Solin, the New York best-selling author of the Smartest series of books states that “the ratio of bad investments advice to sound advice is 10:1.” For those working with the financial media, giving misleading information puts money in their pockets, but when it comes to the security sectors, there is a lot to consider than just earning a living.

Bad Investment Advice Knows No Boundaries
The reason being, the welfare of the investors, is at stake. A Canadian newspaper, The Globe and Mail published an article August 6, 2016, featuring Paul Harris on the “three top stock picks.” The partner and portfolio manager at Avenue Investment Management gives convincing explanations for his stockpiles that would woo some investors to the trading stocks. What the traders do not include in the data is the information on the predictive record of accomplishment.

Laidlaw & Company is an investment banking and brokerage firm that gives personalized advice on banking and wealth management to individuals and institutions in the United States and the United Kingdom. Laidlaw’s investment banking services include raising capital through equity placement with high net worth investors, arranging the national exchange listings AIM-listed transactions on the UK market, trading markets in US as well as initial public offerings. Wealth management services include financial planning, advisory on investment and managing portfolios. Additionally, on the investment banking services, Laidlaw offer stock repurchases, balance sheets optimization, and strategic alliances.

Mr. Matthew D. Eitner ss the CEO and Mr. James P. Ahern the managing partner and Head of Capital Markets at Laidlaw On December 10, 2015, Laidlaw, Matthew Eitner and Ahern received restraining orders from the US District Court for the District of Nevada. Relmada filed a lawsuit against the two for disseminating false and misleading proxy materials; Laidlaw made attempts to take control over Relmada Therapeutics Inc. Laidlaw & Company has its headquarters in New York.